Greek National Organization of Medicines Approves First Antimicrobial Formula for Residual Surface Protection Against SARS-CoV-2 (COVID-19 Virus) for up to 90 Days
ViaClean Technologies, LLC, a Philadelphia-based biotech company, jointly with its distributor and business development partner, Bizos Cavallo Enterprises LLC of Dallas, TX, and their partner, V-Clean Technologies S.A. of Athens, Greece, jointly announced the country of Greece's approval for the use of BIOPROTECT™ RTU on porous and non-porous surfaces in the fight against SARS-CoV-2. Greece has recognized BIOPROTECTTM RTU as inhibiting the growth of harmful bacteria and viruses, including SARS-CoV-2 (COVID virus), on surfaces for up to 90 days.
Having accepted and recognized the antimicrobial surface efficacy of BIOPROTECT™ RTU, Greece's National Organization of Medicines (ΕΟΦ) has approved the unrestricted consumer use of BIOPROTECT™ RTU to inhibit the growth of SARS-CoV-2 and other harmful viruses, bacteria, mold, and mildew, on treated surfaces. This innovative technology has proven to be effective for up to 90 days and has been applied in various public and private environments in Greece, including medical facilities, mass transit, education, commercial facilities, and more.
"ViaClean has been committed to supporting the reopening of Europe throughout the past year, hoping to instill a sense of normality as people navigate these unprecedented times," said ViaClean President and CEO, Greg Tipsord. "With Greece's adoption of BIOPROTECTTM RTU antimicrobial surface protectant, which inhibits the growth of SARS-CoV-2 and other harmful viruses and bacteria on surfaces, we believe Greece will benefit from this proven technology and strengthen their commitment to reach pre-pandemic levels of normalcy for their citizens. We've delivered an effective antimicrobial surface protectant solution that supports our mission of continued research, innovation, and dedication on a global scale."
"At V-Clean Technologies S.A., we have further cemented our commitment to Greece and the ongoing safety of our fellow citizens and visitors through our commitment to bringing innovative, patented technologies to our country to reduce the presence of bacteria, germs, fungi, algae, and other problematic micro-organisms including SARS CoV-2” said Panos Sofianos, President of V-Clean. “We thank the Greek government, and specifically the Ministry of Health and the National Organisation for Medicines (ΕΟΦ), our joint-venture distribution partner, Bizos Cavallo Enterprises and of course, ViaClean Technologies, for their rigor, diligence, and support throughout this process."
In Greece and in other European Member States, where regulatory approvals are pending, the unique non-leaching and non-volatile BIOPROTECTTM RTU formula has proven to be effective at killing harmful microbes and reducing odors for up to 90 days on various surfaces. "We are fortunate and thrilled to have partnered with both V-Clean Technologies and ViaClean Technologies by facilitating the approval process and distribution of BIOPROTECTTM RTU antimicrobial surface protectant for Greece," said Elvin Thibodeaux, Managing Partner of Bizos Cavallo Enterprises. "Our continued efforts will supply this innovative technology exclusively to additional markets, including the European Union and Balkan Peninsula, Russia and more, that are pursuing dynamic relief from the effects of the pandemic over the past 18 months."
In the United States, ViaClean markets the BIOPROTECTUs™ System, which uses patented, registered technologies: SmartTouch®, a List N disinfectant, to disinfect surfaces against viruses, bacteria, and germs, and BIOPROTECT™ RTU antimicrobial surface protectant, to keep surfaces free of odor- and stain-causing bacteria, fungi (mold and mildew), and algae between cleanings, for up to 90 days (3 months). In the United States, however, BIOPROTECT™ RTU is not currently approved or available for use against the SARS-CoV‑2 virus, other viruses, harmful bacteria, or any other harmful microorganisms.
Additional products offered from ViaClean and Bizos Cavallo in the United States, and pending approval in Greece, include the registered BIOPROTECT™ 500 concentrate, registered BIOPROTECTTM D disinfectant, and registered BIOPROTECT™ Hydrating Hand Sanitizer. For more information on ViaClean Technologies and The BIOPROTECTUs™ System, please visit bioprotectworldwide.com. For information on the aforementioned markets or sales with Bizos Cavallo Enterprises, visit www.bizoscavallo.com.
About ViaClean Technologies. LLC
ViaClean Technologies LLC is a biotech company that develops, manufactures, and markets groundbreaking, innovative antimicrobial solutions using environmentally responsible manufacturing processes. ViaClean Technologies' pioneering and proprietary technologies, products, and services provide disinfectants, antimicrobial protectants, and hand sanitizers for commercial and consumer use. ViaClean Technologies' primary mission is to market these advanced antimicrobial formulations to critical industries, manufacturing the registered formulations using environmentally responsible processes. For more information, visit the ViaClean website (bioprotectworldwide.com).
About V-Clean Technologies, S.A.
V-Clean Technologies S.A. is a biotechnology firm based in Athens, Greece that is focused on developing and marketing cutting edge technologies, products and services to meet the challenges and opportunities in Europe, Russia and the Middle East. In conjunction with our pharmaceutical affiliates and partners we strive for innovative and environmentally responsible solutions in an ever-changing marketplace. Having created a strong and sustainable network of strategic partners throughout these regions, we are able to be proactive and effective in providing services ranging from manufacturing, sourcing, logistics and regulatory advisory. For more information about V-Clean Technologies S.A. please visit our website (www.virusclean.gr).
About Bizos Cavallo Enterprises, LLC
Bizos Cavallo Enterprises, LLC is a strategic consulting and operations firm focused on emerging bioscience innovations for public health, strategic alliances, and global investment resources based in Dallas, TX, with offices in New Orleans, LA, and Winston-Salem, NC. In addition, Bizos Cavallo owns the subsidiary, BP&D International, LLC, a global leader in the procurement and the export of premium cultural commodities, including bulk grains, animal proteins, and their respective derivatives. Founded in 2017, Bizos Cavallo's network includes partners and a host of strategic alliances in the United States, Greece, China, South Korea, Japan, Singapore, Dubai, France, Brazil, the West Indies and trade operations in the United Kingdom. For more about Bizos Cavallo, visit the Bizos Cavallo Enterprises website (www.bizoscavallo.com).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713006244/en/
Contact information
Media
Chad Belisario
EVINS Communications
Email: ViaClean@evins.com
Chad Belisario
Bizos Cavallo Enterprises, LLC
Email: media@bizoscavallo.com
Chad Belisario
V-Clean Technologies, Ltd
Email: Info@virusclean.gr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 02:40:00 EET | Press release
Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a monumental year for us, as we enter into a new chapter for our company. Today, we are announcing six additional candidates in our biosimilar pipeline, including vedolizumab and dupilumab. We are making great progress to secure 20 biosimilars in our portfolio by 2030," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We also received the investigational new drug application (IND) clearance for the first novel therapeutic candidate developed by Samsung Bioepis, and plan to advance our clinical program this year. As we broaden our portfolio beyond biosimilars, we will continue our development efforts in anti
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 21:30:00 EET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 19:30:00 EET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 17:00:00 EET | Press release
The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data center expansion (~4%). Crucially, the report finds that this additional demand does not have to result in competition between industry and communities. Today, global water systems proces
Primient to Acquire Full Ownership of Primient Covation, LLC14.1.2026 17:00:00 EET | Press release
Primient, a global leader in biomanufacturing, announced today it has agreed to purchase the remaining ownership interest in Primient Covation, LLC (“Primient Covation”), establishing Primient as the sole owner of the company and marking an exciting new chapter in Primient’s growth in the bioeconomy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114344080/en/ This acquisition is the next step of Primient’s strategy to strengthen Primient’s leadership position in biomanufacturing and builds upon recent announcements, including Primient’s partnership with Sustainea and the creation of the iPROOF venture. Primient Covation stands as a leading force in the U.S. biomanufacturing sector, distinguished by its broad range of biomanufacturing and fermentation expertise. The company was founded in 2000 to supply a variety of end markets, including cosmetics and personal care, textiles, fashion, coatings, functional fluids, and oth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom